All posts by medical

Hamilton Thorne to Announce Q1 2020 Financial Results on May 28 and Hold Conference Call on May 29, 2020 – GlobeNewswire

BEVERLY, Mass. and TORONTO, May 26, 2020 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three-month period ended March 31, 2020 after market close on Thursday, May 28, 2020. The press release, with accompanying financial information, will be posted on the Companys website at http://www.hamiltonthorne.ltd and on http://www.sedar.com.

The Company will follow with a conference call on Friday, May 29, 2020 at 11:00 a.m. EDT to review highlights of the results. All interested parties are welcome to join the conference call by dialing toll free 1-855-223-7309 in North America, or 647-788-4929from other locations, and requesting Conference ID 29985315. A recording of the call will be available on Hamilton Thornes website shortly after the call.

About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thornes customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Read more:
Hamilton Thorne to Announce Q1 2020 Financial Results on May 28 and Hold Conference Call on May 29, 2020 - GlobeNewswire

Powerful properties: how tobacco is being used to fight COVID-19 – Euronews

At the Institute for Plant Molecular and Cellular Biology in Valencia, a team of top scientists are attempting to harness the power of nature.

Using the latest techniques to cultivate and sequence the genome of the Nicotiana Benthamiana, a close relative of the tobacco plant, researchers taking part in the European funded Newcotiana project say they are able to produce tailor-made molecules to fight disease.

Native to Australia, the Nicotiana Benthamiana plant has been used to help produce vaccines and antibodies for viruses such as Ebola.

By injecting other DNA into its leaves, its genes can be modified to create specific pharmaceutical products in very large amounts.

"We give the plants instructions to improve them, to change specific genes. For example, we are interested in having plants that do not flower. We want to grow plants that produce more biomass, because those are the kinds of things we want the plant to do," says Marta Vzquez, a biotechnology research at IBMCP.

Hopes are high the technique, which harnesses the plant's cells and sap, could eventually help pave the way to producing a COVID-19 vaccine. Experts say the approach has several advantages. It can produce large amounts of the required protein, is low-cost compared to other methods and and is safe.

Plants are very useful for researchers as they are another mean of expressing viral proteins or nucleic acids without having to actually work with the causative virus itself. And we can use techniques of synthetic biology to make things like virus-like particles without handling the infectious virus, says George Lomonossoff, a virologist at the John Innes Centre.

The modified plant can generate proteins similar to those found in a human cell. Researchers say a growing number of companies are embracing this technique.

"There are about a hundred groups in the world that are trying to develop SARS COVID-2 vaccines. Some of these groups and private companies are using this plant, whose genome we have sequenced. Making the genome available...will help these firms optimise this production," insists Giovanni Giuliano, Research Director at Italys National Agency for New Technologies, ENEA.

By making the plants genome publicly available, scientists at the EU funded project hope it will speed up the search for new products that will fight both the current and future pandemics.

Here is the original post:
Powerful properties: how tobacco is being used to fight COVID-19 - Euronews

May: glass frogs | News and features – University of Bristol

Glass frogs illustrate a new mechanism of camouflage: 'edge diffusion'. J Barnett

The frogs are always green but appear to brighten and darken depending on the background. J Barnett

Press release issued: 25 May 2020

Glass frogs are well known for their see-through skin but, until now, the reason for this curious feature has received no experimental attention.

A team of scientists from the University of Bristol, McMaster University, and Universidad de Las Amricas Quito, sought to establish the ecological importance of glass frog translucency and, in doing so, have revealed a novel form of camouflage.

Using a combination of behavioural trials in the field, computational visual modelling and a computer-based detection experiment, the study published in PNAS reveals that, while glass frog translucency does act as camouflage, the mechanism differs from that of true transparency.

Lead author, Dr James Barnett who began the research while a PhD student at the University of Bristol and is now based at McMaster University in Canada, said:

The frogs are always green but appear to brighten and darken depending on the background. This change in brightness makes the frogs a closer match to their immediate surroundings, which are predominantly made up of green leaves. We also found that the legs are more translucent than the body and so when the legs are held tucked to the frogs sides at rest, this creates a diffuse gradient from leaf colour to frog colour rather than a more salient sharp edge. This suggests a novel form of camouflage: edge diffusion.

Dr Barnett said scientific debate had often been skeptical of the degree to which glass frogs can be called transparent.

Transparency is, at face value, the perfect camouflage. It is relatively common in aquatic species where animal tissue shares a similar refractive index to the surrounding water. However, air and tissue are quite different in their refractive indices, so transparency is predicted to be less effective in terrestrial species. Indeed, terrestrial examples are rare. Although glass frogs are one commonly cited example of terrestrial transparency, their sparse green pigmentation means they are better described as translucent, said Dr Barnett.

Dr Barnetts PhD was supervised by Professor Nick Scott-Samuel, an expert in visual perception from the University of Bristols School of Psychological Sciences, and Innes Cuthill, Professor of Behavioural Ecology from Bristols School of Biological Sciences. Professor Scott-Samuel said:

Our study addresses a question that has been the topic of much speculation, both among the public and the scientific community. We now have good evidence that the frogs glass-like appearance is, indeed, a form of camouflage.

Professor Cuthill said: Animal camouflage has long been a textbook example of the power of Darwinian natural selection. However, in truth, we are only beginning to unravel how different forms of camouflage actually work. Glass frogs illustrate a new mechanism that we hadnt really considered before.

Paper:

Imperfect transparency and camouflage in glass frogs by J. Barnett et al in PNAS.

School of Biological Sciences

Research in the School of Biological Sciences spans the full range of biological disciplines, from genomics and cell biology, through diverse aspects of whole organism biology and evolution, to population biology and ecosystem services.

Our research is organised around four main themes that reflect our strengths and interests: Evolutionary Biology; Animal Behaviour and Sensory Biology; Plant and Agricultural Sciences; and Ecology and Environmental Change.

Animal behaviour and sensory biology:

Our research is aimed at understanding the adaptive significance of behaviour, from underlying mechanisms (how, or proximate, questions) through evolutionary explanations of function (why, or ultimate, questions) to interspecific interactions at the community level.

The approach is strongly interdisciplinary, using diverse physiological, biomechanical, neurological and molecular techniques, theoretical modelling and behavioural experiments in both laboratory and natural populations to link from the genetic foundations through to the evolution of behaviour and sensory systems.

Our study systems range from bats to birds and bees, mongooses to moths, fish to flies, and dolphins to decapods.

School of Pyschological Sciences

The School of Psychological Science is a vibrant, friendly, and exciting place to work and study in. We offer accredited undergraduate and postgraduate taught courses, and have a lively and productive community of PhD students and research staff.

Our students benefit from being taught and supervised in an intellectually rich environment by staff who are working at the forefront of the discipline. Members of the School have won a number of awards for their research, highlighting their contribution to Psychology nationally and internationally.

Our research spans developmental, social, cognitive and biological psychology, neuropsychology, and vision science. It has applications in areas ranging from human performance, memory, and communication to addiction and neurological disease.

Read the rest here:
May: glass frogs | News and features - University of Bristol

What is Science? A Guide to Understanding Sciencefiction – Breakfast Television Toronto

rogerstestuser | posted Tuesday, May 26th, 2020

Whats Science? Whats Science Fiction?

Science is the study of temperament, of its own processes along with the world, and into it. Its the research of both the natural and synthetic phenomena and so it has physics, chemistry, http://www.hausarbeit-ghostwriter.at/ psychology, psychology, astronomy, meteorology, geology, geophysics, and a lot of other sciences.

What is a Concept in Science? Since we have already established, Science may be the analysis of character and what happens to this and so we want concepts to simply help us understand the world we dwell in. While in the case of scientific tests of a system, we are able to group them into categories, specifically Science, Chemical Science, Biological Science, Quantum Physics, and Space Science.

Although I Bachelorarbeit Ghostwriter Preis prefer to categorize theories as theories in separate and unique ways for each category, there is no set pattern or rule that I can recommend. For example, if one thinks that all the theories are mere opinions with no validity, then that person would be guilty of making a single theory, a Theory in Science.

Theories in Physical Science bargain with laws of character ; they clarify how a world behaves and at which it will go in the future. A-Theory at Physical Science is thought of as a series of predictions about how things may act which will be analyzed through observation.

Newtons concepts were designed from experiments that hed carried out on apples that were diminishing. These experiments are known as Newtons Laws of Motion.

Back in Chemical Science, theories might be categorized as physical, biological, or social/biological and therefore on. Likewise Quantum Physics deals.

Physical Sciences includesPhysiology, Behavior, and Evolution, Chemistry, Metaphysics, Chemistry, Physics, Astronomy, Earth Sciences Aeronautics Marine Biology, Nano Technology, Genetics, Immunology, Cell Biology, Genetics, Pathology, Human Biology. These classes would be the 4 leading branches of the Actual sciences.

Biological Science copes with all living strategies as well as their development, expansion, and reproduction. As an instance, Darwinism explains the evolution of species by means of natural selection notions have been used to study different forms of living.

Social/biological Science concentrates how humans connect solely with also ghostwriting the world and some other people generally. Sociobiology discusses humans impact the environment around them through their own consumption, research, schooling, etc.

Area Science can be involved with the analysis of just how exactly, including the planets, stars, and galaxiesand orbit the center of this Milky Way galaxy. Space Science comprises Planetary Science, Astrophysics, Astronomy, Earth Sciences, Cosmology, Geophysics, and Numerical Arithmetic.

What is Science Fiction? Science fiction is just really a fictionalized interpretation of what may happen inside the universe. Its simply within such a fashion that we are able to test our notions.

Here is the original post:
What is Science? A Guide to Understanding Sciencefiction - Breakfast Television Toronto

Cancer Stem Cells Reliance on a Key Amino Acid Could Be an Exploitable Weakness – On Cancer – Memorial Sloan Kettering

By Matthew Tontonoz Tuesday, May 26, 2020

Starving skin cancer tumors of serine increases cancer stem cell differentiation in mice. In this image, skin stem cells undergoing differentiation are magenta and those remaining as stem cells are green.

Summary

A team of scientists at the Sloan Kettering Institute and The Rockefeller University has discovered that cancer stem cells rely on a steady external supply of the amino acid serine. This dependency makes them vulnerable to restrictions on this supply, a discovery that could potentially be exploited therapeutically.

In recent years, cancer biologists have come to understand that metabolism the way that cells acquire and use nutrients can directly affect their tendency to become cancerous.

SKI cell biologist Lydia Finley and colleagues in the Elaine Fuchs lab at The Rockefeller University have now deepened knowledge of this relationship in the context of squamous cell carcinoma, a cancer that arises from stem cells in the skin. Using mouse models and cells growing in tissue culture, they found that the amount of the amino acid serine present in a stem cells environment influences its decision to keep dividing or to grow up (differentiate). Differentiated cells generally do not form cancer.

The stem cells that give rise to squamous cell carcinoma seem to be highly dependent on extracellular serine for their growth, Dr. Finley says. Trying to starve these cells of this source of serine could be a strategy to try to curb their growth by forcing them to differentiate.

A normal stem cell will respond to a shortage of extracellular serine by synthesizing more. Atthe same time, they will begin differentiating: The biochemical pathways involved with serine synthesis interact with proteins called histones that wrap DNA like a spool of thread and allow specific genes to be turned on. Stem cells with cancer-predisposing mutations, on the other hand, seem intent onavoiding new serine synthesis.

Cancer stem cells heightened reliance on extracellular serine reflects what Dr. Finley calls metabolic rewiring: By relying on extracellular serine, the cancer stem cells can avoid serine synthesis, with the happy side effect (for the cancer cell) that the path toward differentiation is blocked.

Our findings link the nutrients that a skin stem cell consumes to their identity and their ability to initiate a tumor, says Sanjeethan Baksh, a Tri-Institutional MD/PhD student in the Fuchs lab and the papers first author. Not only do nutrients allow stem cells and cancer cells to grow, but our study also shows that metabolism directly regulates gene expression programs important for cancer stem cell identity.

Although restricting serine in the diet is not feasible in humans, the team is currently looking for ways that they might be able to interfere with cancer stem cells ability to take up serine in the hope of curbing cancer growth.

The findings were reported on May 25 in the journal Nature Cell Biology.

This study received financial support from the Howard Hughes Medical Institute, the National Institutes of Health (grants R01-AR31737, F31CA236465, F30CA236239-01, and 1F32AR073105), the Human Frontiers Science Program, the European Molecular Biology Organization, NYSTEM (CO29559), The Starr Foundation, the Damon Runyon Cancer Research Foundation, the Concern Foundation, the Anna Fuller Fund, The Edward Mallinckrodt, Jr. Foundation, and the Memorial Sloan Kettering Cancer Center Support Grant P30 CA008748. The study authors declare no competing interests.

Go here to read the rest:
Cancer Stem Cells Reliance on a Key Amino Acid Could Be an Exploitable Weakness - On Cancer - Memorial Sloan Kettering

argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis | Antibodies | News…

DetailsCategory: AntibodiesPublished on Tuesday, 26 May 2020 10:23Hits: 154

BREDA, The Netherlands / GHENT, Belgium I May 26, 2020 I argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced positive topline data from the pivotal ADAPT trial of efgartigimod. ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score among acetylcholine receptor-antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) patients. Responders are defined as having at least a two-point improvement on the MG-ADL score for at least four consecutive weeks. Based on these results, argenx plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) by the end of 2020.

Highlights of topline ADAPT data

The efgartigimod data showed rapid and robust responses in people with gMG, as well as a favorable tolerability profile, said James F. Howard Jr., M.D., Professor of Neurology (Neuromuscular Disease), Medicine and Allied Health, Department of Neurology, The University of North Carolina at Chapel Hill School of Medicine and principal investigator for the ADAPT trial. Patients with this devastating disease can experience chronic and potentially life-threatening muscle weakness that has a major impact on their quality of life, and more treatment options are needed. These data are very encouraging as they show efgartigimod has potential to make a meaningful impact on daily living activities, and we are hopeful they will lead to a new treatment being available for the gMG community.

With the ADAPT trial, we set out to evaluate efgartigimods ability to redefine the treatment paradigm for people living with gMG. The data showed that efgartigimod drove fast and deep responses, including in a proportion of patients who achieved minimal or no symptoms after treatment. In addition, we saw responses that lasted beyond eight or 12 weeks, supporting our plans to offer individualized dosing schedules that are purpose-fit to the variability in disease course that gMG patients experience, commented Wim Parys, M.D., Chief Medical Officer of argenx. Based on these data, we intend to submit a BLA for efgartigimod to the FDA before the end of the year, taking us one step closer to potentially making efgartigimod available to patients in 2021. All of us at argenx want to thank the patients and healthcare providers who participated in the ADAPT trial. ADAPT is the first pivotal trial of efgartigimod and these data further our confidence in its broad opportunity in other severe, IgG-mediated autoimmune diseases.

Additional ADAPT results, including secondary endpoints and prespecified analyses

Detailed data from the ADAPT trial will be submitted for presentation at a future medical meeting.

Phase 3 ADAPT Trial DesignThe Phase 3 ADAPT trial was a randomized, double-blind, placebo-controlled, multi-center, global trial evaluating the safety and efficacy of efgartigimod in patients with gMG. A total of 167 adult patients with gMG in North America, Europe and Japan enrolled in the trial and were treated. Enrolled patients had a confirmed gMG diagnosis and an MG-ADL total score of five or greater. Patients were on a stable dose of at least one gMG treatment prior to randomization, including acetylcholinesterase inhibitors, corticosteroids or nonsteroidal immunosuppressive drugs, and were required to remain on that stable dose throughout the primary trial. Patients were eligible to enroll in ADAPT regardless of antibody status, including patients with AChR antibodies (AChR-Ab+) and patients where AChR antibodies were not detected.

Patients were randomized in a 1:1 ratio to receive efgartigimod or placebo for a total of 26 weeks as part of the primary trial. ADAPT was designed to enable an individualized treatment approach with an initial treatment cycle followed by a variable number of subsequent treatment cycles. Treatment cycles consist of four infusions of efgartigimod (10mg/kg IV) or placebo at weekly intervals. Retreatment with additional treatment cycles was initiated according to clinical response. The primary endpoint was the number of AChR-Ab+ patients who achieved a response on the MG-ADL score defined by at least a two-point improvement for four or more consecutive weeks.

After the 26-week primary ADAPT trial, patients were eligible to roll-over into an open-label extension, ADAPT Plus.

About Efgartigimod

Efgartigimod is a first-in-class antibody fragment designed to reduce disease-causing immunoglobulin G (IgG) antibodies and block the IgG recycling process. Efgartigimod binds to the neonatal Fc receptor (FcRn), which is widely expressed throughout the body and plays a central role in rescuing IgG antibodies from degradation. Blocking FcRn reduces IgG antibody levels representing a logical potential therapeutic approach for several autoimmune diseases known to be driven by disease-causing IgG antibodies, including: myasthenia gravis (MG), a chronic disease that causes muscle weakness; pemphigus vulgaris (PV), a chronic disease characterized by severe blistering of the skin; immune thrombocytopenia (ITP), a chronic bruising and bleeding disease; and chronic inflammatory demyelinating polyneuropathy (CIDP), a neurological disease leading to impaired motor function.

About Myasthenia Gravis (MG)

MG is a rare and chronic autoimmune disease where IgG antibodies disrupt communication between nerves and muscles, causing debilitating and potentially life-threatening muscle weakness. More than 85% of people with MG progress to generalized MG (gMG) within 18 months, where muscles throughout the body may be affected, resulting in extreme fatigue and difficulties with facial expression, speech, swallowing and mobility. In more life-threatening cases, MG can affect the muscles responsible for breathing. Patients with confirmed AChR antibodies account for 80-90% of the total gMG population. There are approximately 65,000 people in the United States and 20,000 people in Japan living with the disease.

About argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States and Japan. For more information, visit http://www.argenx.com and follow us on LinkedIn at https://www.linkedin.com/company/argenx/.

SOURCE: argenx

Read the original:
argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis | Antibodies | News...

Change in Orion Group Executive Management Board as of 1 June 2020: Professor Outi Vaarala appointed as Senior Vice President for Research and…

Outi Vaarala photo

Professor Outi Vaarala, Senior Vice President for Research and Development and member of the Executive Management Board of the Orion Group, as of 1 June 2020.

ORION CORPORATION STOCK EXCHANGE RELEASE 25 MAY 2020 AT 4.20 p.m. EEST

Change in Orion Group Executive Management Board as of 1 June 2020: Professor Outi Vaarala appointed as Senior Vice President for Research and Development

Professor Outi Vaarala, M.D., Ph.D. has been appointed Senior Vice President for Research and Development and member of the Executive Management Board of the Orion Group, as of 1 June 2020. Vaarala has held the position of Vice President, Oncology Research in Orions Research and Development as of 10 June 2019. Prior to Orion, Vaarala led drug discovery and development from target identification to clinical Phase 2 studies in Respiratory Inflammation and Autoimmunity therapy area, first at AstraZeneca, Sweden, and later at Medimmune/AstraZeneca, USA.

Outi Vaarala is a medical doctor (University of Helsinki) and has a PhD in immunology. Outi Vaarala was appointed as a Professor of Pediatric Immunology, Linkoping University, Sweden, in 2000, and as a Professor of Autoimmune Diseases, Lund University, Sweden, in 2015.

Timo Lappalainen, President and CEO, says:

Orions Research and Development is in an interesting phase. Our operations have been developed into a recognized world-class organization that has also achieved remarkable results. Outi Vaarala has excellent background and experience from various leadership positions in Research and Development in the international pharmaceutical industry as well as a long experience of immunology and remarkablecareer in the academy. She has published more than 200 peer-reviewed scientific articles in internationally renowned scientific journals. I warmly welcome Outi as a member of Orions Executive Management Board.

Outi Vaarala says:

During the past year when leading Oncology Research team at Orion, I have recognised the fabulous opportunities in Orion based on the knowledge and expertise across the organisation. This makes me excited about this new challenge ahead me. Co-operation and international networking is a key to success because nobody can develop drugs alone. Finland and Orion have a lot to offer for the proprietary drug discovery, and at the same time international networking is a crucial part of the operations of Orions Research and Development. In my new position, I want to emphasise this.

The CV of Outi Vaarala and a photo of her are attached.

Orion Corporation

Timo Lappalainen Olli HuotariPresident and CEO Senior Vice President, Corporate Functions

Contact person:

Timo Lappalainen, President and CEO, phone +358 50966 3692

Contact person for media:Terhi Ormio, Vice President, Communications, phone +358 50966 4646, terhi.ormio@orion.fi

APPENDIX:

The CV of Outi Vaarala

Outi Vaarala

MD, University of Helsinki, 1990 PhD in immunology, University of Helsinki, 1991Professor of Pediatric Immunology, Linkoping University, Sweden, 2000 Professor of Autoimmune Diseases, Lund University, Sweden, 2015

Born 1962

Senior Vice President for Research and Development, Orion Corporation as of 1 June 2020

Career

Positions of trust2005-2014 Permanent expert at the European Medicines Agency (EMA)

PublicationsMore than 200 peer-reviewed scientific articles in internationally renowned scientific journals (as in Science Translational Medicine, Cell Host Microbes, JAMA, New England Journal of Medicine, the Lancet, and Journal of Immunology).

Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orion.fi/en http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Read the original here:
Change in Orion Group Executive Management Board as of 1 June 2020: Professor Outi Vaarala appointed as Senior Vice President for Research and...

RAPT Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference – GlobeNewswire

SOUTH SAN FRANCISCO, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical companyfocused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present a corporate update and company overview at the Jefferies 2020 Healthcare Conference on Tuesday, June 2nd at 9:30 a.m. Eastern Time.

A live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website athttps://investors.rapt.com/events-and-presentations. Please connect to the website 10 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

AboutRAPT Therapeutics, Inc.RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2)), that are in the discovery stage of development.

Media Contact:Angela Bittingmedia@rapt.com(925) 202-6211

Investor Contact:Sylvia Wheelerswheeler@wheelhouselsa.com

View original post here:
RAPT Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference - GlobeNewswire

$1.05 Million Grant from Chan Zuckerberg Initiative for Penn Researchers – UPENN Almanac

$1.05 Million Grant from Chan Zuckerberg Initiative for Penn Researchers

Two teams of researchers, one from the Perelman School of Medicine at the University of Pennsylvania, and the other from Penn and Childrens Hospital of Philadelphia (CHOP), were each awarded $525,000 in funding to explore emerging ideas regarding the role of inflammation in disease.

The number of overweight or obese infants and young children, from birth to five years, increased from 32 million globally in 1990 to 41 million in 2016. A similar prevalence is observed in older children and adolescents. The vast majority of overweight or obese children live in developing countries or belong to underprivileged communities.

One team of researchers, led by Jorge Henao-Mejia, an assistant professor of pathology and laboratory medicine, Sarah Henrickson, an assistant professor of pediatrics, and Golnaz Vahedi, an assistant professor of genetics, plans to use the award to investigate the impacts of childhood obesity on immune function. Dr. Henao-Mejia is also affiliated with the department of pathology at CHOP, and Dr. Henrickson is an attending physician of allergy and immunology at CHOP.

This award will allow us to map the impact of obesity in the immune system in children and the long-term immunological consequences of this disorder, Dr. Henao-Mejia said. As inflammation plays a critical role in the majority of obesity associated diseases, our research will be the first step to elucidate alterations in the immune system that contribute to disease progression in obese children.

Another team, led by Kellie Ann Jurado, Presidential Assistant Professor of Microbiology, Monica Mainigi, William Shippen, Jr. Assistant Professor of Human Reproduction, and Donegeun (Dan) Huh, associate professor of bioengineering at the School of Engineering and Applied Science, plans to explore how maternal and fetal cells respond to specific inflammatory signals and analyze the network of placental cells and immune cells that impact pregnancy outcomes in chronic inflammatory diseases.

The grant partners three investigators with diverse expertisean experimental immunobiologist, a reproductive and infertility clinician-scientist, and a bioengineer who specializes in biometric technology to investigate the role of the maternal inflammation on early pregnancy establishment.

We know that communication between the mother and the fetuss immune system is critical in pregnancy, Dr. Mainigi said. Results from this study will provide insight into immunological mechanisms that govern pregnancy, an understanding essential for proper diagnosis, prevention and treatment of infertility and pregnancy complications.

The Chan Zuckerberg Initiative has awarded grants to 29 teams of researchers around the world to study how inflammation influences disease.

Excerpt from:
$1.05 Million Grant from Chan Zuckerberg Initiative for Penn Researchers - UPENN Almanac

Every healthcare worker should be tested for COVID-19 every few weeks, expert says – Newstalk 106-108 fm

An immunology expert has called for all healthcare and nursing home workers to be tested for COVID-19 every two to three weeks - saying its a no-brainer to help limit transmission of the virus.

Dr Tomas Ryan, Assistant Professor at the school of biochemistry and immunology at Trinity College Dublin, says international studies have shown that mass testing of health workers is the best investment in testing a country can make.

Latest figures show that7,842 of the confirmed coronavirus cases here are associated with healthcare workers - nearly 30% of the total.

Speaking on The Pat Kenny Show, Dr Ryan said thats an extraordinarily high number.

Every healthcare worker should be tested for COVID-19 every few weeks, expert says

00:00:00 / 00:00:00

He said: There have been some very disturbing studies coming out from the UK showing that between 3% and 5% of all healthcare workers in England have the virus and 50% of those people are totally asymptomatic.

Healthcare workers are spreading the virus in our hospitals theyre spreading it to other healthcare workers, and theyre spreading it to patients. Then patients are leaving hospital and spreading it to other people.

We absolutely need to be testing every healthcare worker - and I would say every nursing home or care worker - every two to three weeks, regardless of whether they have symptoms or whether theyve had contact with someone who has had symptoms.

If you do routine testing of all healthcare workers or people in these high-risk scenarios, you reduce transmission in the overall population by 30% - its a no-brainer: we should just do it, but were not doing it.

Dr Ryan also addressed the high rate of COVID-19 clusters in nursing homes - saying its been one of the tragedies of the pandemic in this country.

He said that Ireland is not unique in Europe in having experienced such problems in nursing homes, but explained that other countries - particularly in Asia - took quick action to deal with the issue, including instructing staff to wear face masks at all times.

He told Pat: What I do think is that the State - NPHET - should have taken consolidated, preempted action in adequately instructing and advising nursing homes.

I think that visitor restrictions should have been put in place in early March in a very clear manner for all nursing homes - I think that would have made a huge amount of difference, as well as staff education and masks.

We should have stopped all visitors to nursing homes on February 29th, when the first case came into Ireland.

Nursing Homes Ireland stopped visits in their private nursing homes in early March - but Dr Ryan suggested that seems to have been contradicted by NPHET shortly after.

Dr Ryan said it was bizarre for health officials to suggest visitors did not bring cases of the virus into nursing homes.

He also observed: Sometimes I think NPHET and indeed the Department of Health underestimate how scientifically-literate a population we currently have in Ireland.

Everybody is very well-informed on the basic biology of COVID-19. We know it spreads pre-symptomatically - weve known that from March.

His comments come as the Dil COVID committee today hears from representatives from the sector about the situation in nursing homes.

Original post:
Every healthcare worker should be tested for COVID-19 every few weeks, expert says - Newstalk 106-108 fm